Thrombomodulin Alfa ( DrugBank: Thrombomodulin Alfa )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-163326 | 01/5/2016 | 22/07/2016 | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) | Intervention name : ART-123 INN of the intervention : thrombomodulin alfa Dosage And administration of the intervention : 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy Control intervention name : Placebo Dosage And administration of the control intervention : Placebo by intravenous drip infusion in addition to standard of care steroid therapy | ASAHI KASEI PHARMA CORPORATION | NULL | recruiting | 40 | 85 | BOTH | Phase 3 | NULL |